Significados de meet amplification en inglés

Neither the T790M mutation nor MET amplification was apparent in regrown tumors.

Patients with acquired MET amplification showed worse PFS on anti-EGFRs.

However, only MET amplification by FISH and Met expression by SRM were independent prognostic biomarkers.

We found Met amplification to be the most significant oncogenic event in these radiation-induced gliomas.

Apart from this, there was no difference in other mechanisms including MET amplification and histological transformation.

We propose clearly defined amplification scores and provide epidemiologic data on MET amplification in lung cancer.

Conclusion: MET amplification is not a mutually exclusive genetic event in therapy-naïve non-small cell lung cancer.

MET amplification was recently found to be a mechanism of escape from the anticancer effect of EGFR inhibitors.

Importantly, MET amplifications occur at equal frequencies in squamous and adenocarcinomas without or with EGFR or KRAS mutations.

In this study, we aimed to investigate MET amplification status in adeno- and squamous cell carcinomas of the lung.

Background: Combined MET and BRAF inhibition showed clinical benefit in a patient with rectal cancer carrying BRAFV600E and MET amplification.

Lung cancer is a leading cause of death worldwide and MET amplification is a major therapeutic limitation in acquired-resistance lung cancer.

We report a patient with a CUP harboring a MET amplification with a complete metabolic response to crizotinib despite also harboring a KRAS mutation.

EBC1 cells, which have MET amplification and are sensitive to TKIs against MET, were used to generate multiple clones with AR to a MET-TKI.

Conclusion: MET amplification defines a small and aggressive subset of GEC with indications of transient sensitivity to the targeted MET inhibitor crizotinib (PF-02341066).

Conclusions: In patients with recurrent=metastatic gastric cancer, MET amplification and strong protein expression are not rare and appear to be significantly associated with unfavorable clinical outcomes.